Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ackermann

Showing results (201-210 of 215) with videos related to

Pageof 22
Sort By:
Plos One|September 2, 2016
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsChristoph J Niemietz, Vanessa Sauer, Jacqueline Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Predictive role of interphase cytogenetics for survival of patients with multiple myelomaR Königsberg, N Zojer, J Ackermann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 30, 2016
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesElizabeth J Ackermann, Shuling Guo, Merrill D Benson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Investigational New Drugs|March 21, 2017
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumorsA Stathis, D Hess, R von Moos, et al.
Muscle & Nerve|July 13, 2020
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosisP James B Dyck, John C Kincaid, Janice F Wiesman, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 21, 2023
Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular CarcinomaS Mahmoudi, S Bernatz, J Ackermann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Muscle & Nerve|July 13, 2020
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosisP James B Dyck, Teresa Coelho, Marcia Waddington Cruz, et al.
Pageof 22

Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
Plos One|September 2, 2016
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsChristoph J Niemietz, Vanessa Sauer, Jacqueline Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Predictive role of interphase cytogenetics for survival of patients with multiple myelomaR Königsberg, N Zojer, J Ackermann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 30, 2016
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesElizabeth J Ackermann, Shuling Guo, Merrill D Benson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Investigational New Drugs|March 21, 2017
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumorsA Stathis, D Hess, R von Moos, et al.
Muscle & Nerve|July 13, 2020
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosisP James B Dyck, John C Kincaid, Janice F Wiesman, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 21, 2023
Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular CarcinomaS Mahmoudi, S Bernatz, J Ackermann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Muscle & Nerve|July 13, 2020
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosisP James B Dyck, Teresa Coelho, Marcia Waddington Cruz, et al.
Pageof 22